

Neuro-Oncology Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

1L

NRG-BN011

MGMT methylated only

Randomized: RT+TMZ vs RT+TMZ+CCNU

Coord: Hanh Ngo

Accrual: 2/5

2L

UCI 22-58

Only Part C open

Randomized: Vaccine vs CCNU

Coord: Daniel Na

Accrual: 0/6

NRG BN010

Randomized: Monotherapy + FSRT vs
Combination therapy + FSRT

Pending IRB approval

Mutations- diffuse midline glioma

UCI 22-83

H3K K27M mutant mid-line glioma

Randomized: ONC201 vs Placebo

Coord: Hanh Ngo

Accrual: 0/4

UCI 23-67

Phase 1 only; monotherapy; needs DLL#
expression

Pending contract execution



Open to Accrual
 Low Accruing
 Pending Activation/Suspended

LGG

1L

Alliance N0577
1p/19q co-deletion

Randomized: TMZ vs PCV

Coord: Hanh Ngo
Accrual: 2/5

2L

UCI 23-67

Phase 1 only; monotherapy; needs DLL#
expression

Pending contract execution

HGG

UCI 23-67

Phase 1 only; monotherapy; needs DLL#
expression

Pending contract execution



Meningioma

1L

NRG-BN003
Randomized: Observation vs RT
Coord: Hanh Ngo
Accrual: 2/5

2L

UCI 20-152
Cohort 2 open (non-heavily pre-treated)
Coord: Daniel Na
Accrual: 7/10

A071401
Only AKT1/PIK3CA/PTEN arm open
Coord: Daniel Na
Accrual: 1/3

ETCTN 10186
 Phase II: Nivo + Ipi + Radiosurgery
 Suspended

A071601
Only recurrent arm open
Coord: Hanh Ngo
Accrual: 3/5

Craniopharyngioma



2L

NRG BN012

Phase III: Pre-operative Stereotactic RT vs
Post-operative Stereotactic RT

Coord: Daniel Na

Accrual: 2/6

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended



PCNSL

1L

UCI 21-77
Part A: MRT + Tirabrutinib

Coord: Daniel Na
Accrual: 1/6

2L

UCI 21-77
Part B: Tirabrutinib monotherapy

Slot Request Required

Coord: Daniel Na
Accrual: 1/6

Rare CNS cancers

UCI 20-152
Cohort 2 open (non-heavily pre-treated)

Coord: Daniel Na
Accrual: 7/10